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ABSTRACT 
Objectives: Diarrhea is one of the main symptoms of Crohn's disease (CD). It is usually significantly 
improved with specific CD treatments, loperamide or cholestyramine. However, in some cases, 
diarrhea becomes refractory. The aim of this study was to assess the safety and efficacy of octreotide 
in this situation. 
Materials and methods: Fifteen patients with CD refractory diarrhea defined by at least an average of 
five smooth or liquid stools per day despite an optimized CD treatment were included from three 
Belgian centers. Two patients were lost to follow-up. A subcutaneous injection of l00µg octreotide was 
performed three times a day during three days. When the drug had been well tolerated, an 
intramuscular injection of 30 mg octreotide (Sandostatin® LAR 30) was realized. Evaluation was done 
at day 31. The primary endpoint was to assess the effect on the mean number of smooth or liquid 
stools per day. 
Results: A significant reduction (p = 0.0001) of the average number of smooth or liquid stools over the 
last seven days was observed between baseline and day 31. The maximum number of smooth or 
liquid stools also significantly decreased (p = 0.0009). Four patients (26.7%) presented mild 
nonspecific adverse events but no serious one. We also observed a significant decrease (p = 0.0006) 
of the Harvey-Bradshaw Index (HBI) and a significant improvement (p = 0.0012) of the inflammatory 
bowel disease questionnaire (IBDQ). 
Conclusions: In this uncontrolled open-label study, octreotide appeared safe and effective in CD 
refractory diarrhea, in addition to CD treatments. It significantly improved the number of liquid or 
smooth stools, the HBI and the IBDQ. 
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Introduction 
Diarrhea is one of the main symptoms of Crohn's disease (CD). Its mechanisms are complex and 
multifactorial. Malabsorption, osmotic mechanisms, secretory, and motility anomalies may be involved. 
Diarrhea is usually significantly improved by specific CD treatments including steroids, 
immunosuppressive drugs, and biologics. Loperamide and cholestyramine may also be useful. 
However, in some cases, diarrhea persists, and becomes refractory because of an incomplete control 
of the intestinal inflammatory reaction despite an optimization of CD treatment or due to persisting 
functional diarrhea despite a complete control of the intestinal inflammatory reaction. In these 
situations, octreotide, through its effects on the gastrointestinal tract secretion and motility [1-3] and its 
potential immunomodulatory effect [4] may be useful. Octreotide is indeed already used in some cases 
of CD associated refractory diarrhea although no clear evidence of its efficacy is available in the 
literature. The aim of this study was thus to assess the safety and efficacy of octreotide in CD 
refractory diarrhea, in addition to CD treatments. 
Materials and methods 
The protocol was approved by the Ethics committee of Liège University Hospital in June 2011. Before 
undergoing any study assessment, patients gave their written informed consent. 
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CD patients, according to Lennard-Jones criteria [5] were prospectively recruited from three Belgian 
regional and University centers: Center Hospitalier Chrétien CHC Liège, Center Hospitalier Régional 
de la Citadelle CHR Liège, University Hospital CHU Liège. 
Study design 
To be included in the study, the CD patients had to be aged eighteen or older, and to present 
refractory diarrhea. Refractory diarrhea was defined by at least a mean of five smooth or liquid stools 
per day (mean of the number of stools per day over the last seven days prior to baseline) despite a 
normal C-reactive protein (CRP) and an optimized specific CD treatment including 
immunosuppressive drugs and/or anti-TNF. We used the Bristol Stool Scale [6] to evaluate the 
consistency of the stools. Diarrhea had also to be refractory to loperamide and/or cholestyramine. To 
be considered refractory to these drugs, the patients had to have insufficient control of the diarrhea 
according to their own assessment, with either 8x42mg of loperamide and/or 2x4g of cholestyramine. 
They were also considered refractory if they could not tolerate these drugs. Patients with previous 
surgical resection could be included in the study provided that the intervention had been done at least 
six months before the inclusion in the trial. 
Patients could not be included in the study if they presented a known allergy or intolerance to 
octreotide. They were also excluded if they had diarrhea due to small bowel microbial proliferation, 
lactose intolerance, irradiation, chemotherapy, neoplasia, or ischemia. Small bowel microbial 
proliferation was excluded by either a breath test or by an absence of improvement after a course of 
antibiotics. In addition, the inclusion in the study was not allowed if they presented an immediate need 
for surgery, a significant dehydration with the need for intravenous saline perfusion or a severe 
malnutrition with a Body Mass Index (BMI) <16 with the need for enteral or parenteral nutrition. Finally, 
a Harvey-Bradshaw Index (HBI) [7];>13 or a sub score for pain or general wellbeing >2 were also 
exclusion criteria. 
Mesalazine was allowed at a stable dosage for at least three months. Methylprednisolone was 
tolerated at a dosage below 24 mg and stable for two weeks while budesonide was tolerated at a 
dosage equal or below 6mg and stable for two weeks. Azathioprine, 6-mercaptopurine, and 
methotrexate were permitted at a stable dosage for at least three months. Infliximab treatment was 
approved, but day 0 of the present study had to correspond to day 15 to day 28 after the last 
perfusion, and no new perfusion could be performed during the 31 days of the study. Antibiotics for CD 
were allowed at a stable dosage for at least two weeks while antibiotics for another indication were 
only permitted for a short-course of treatment. Loperamide therapy was allowed at a maximum dose of 
3 x 2mg/d and had to remain stable throughout the study while cholestyramine was permitted at a 
maximum dosage of 2 x 4g/d and had also to remain stable throughout the study. 
Treatment evaluated during the study 
A subcutaneous injection of 100 µg of octreotide (Sandostatin® 100µg/ml s.c.) was performed three 
times a day during the first three days after baseline. When the drug had been well tolerated, an 
intramuscular injection of 30 mg of octreotide (Sandostatin® LAR 30) was realized on day 3. 
Patients discontinued the trial in case of any CD treatment change, including any change in the 
dosage of CD treatment, CD surgery, and intolerance or study treatment side-effects. 
Endpoints 
The primary endpoints were to assess the safety and the effect of subcutaneous octreotide 100 µg 
three times a day for three days followed by one intramuscular injection of octreotide 30 mg LAR on 
CD refractory diarrhea. Evaluation was done at day 31. The criterion of judgment was the mean 
number of smooth or liquid stools per day by comparing the last seven days before baseline and 
before day 31 (stool frequency being collected by a patient on a daily basis all over the study period in 
a diary). 
As secondary endpoint, we evaluated the effect of octreotide therapy on the mean number and on the 
maximum number of bowel movements per day between baseline and day 31. We also assessed the 
number of patients responding to octreotide. A response was defined by a decrease of at least 25% of 
the mean number of liquid or smooth stools per day between baseline and day 31. The proportion of 
patients with a significant reduction in the number of liquid or smooth stools per day, defined by a 
reduction of at least 2, was also assessed. Moreover, we assessed the effect of octreotide on CD 
activity by calculating the HBI, on CRP (measured locally on day 0 and 31), on fecal calprotectin 
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(measured centrally at CHU Liège, ELISA Bühlmann) and on health related quality of life Inflammatory 
bowel Disease Questionnaire (IBDQ) [8]. 
Statistical analysis 
The primary endpoint was to assess the effect of octreotide on the mean number of smooth or liquid 
stools per day. These mean numbers were compared between the seven days preceding day 0 and 
day 31 in the thirteen patients for whom we had these two measurements by a paired f-test (two 
patients were lost to follow-up). An intent-to-treat analysis was performed considering patients lost to 
follow-up as non-responders and keeping the same number of stools as at baseline. 
The evolution of the other parameters included in the secondary endpoints (total number of bowel 
movements, HBI, CRP, IBDQ, and fecal calprotectin) was assessed in the same way. Demographic 
and clinical characteristics were compared between responders and non-responders. 
Results were presented as means, standard deviations (SD), medians, and interquartile ranges (IQR) 
for continuous variables and as tables of frequencies for categorical variables. Absolute differences 
(between day 0 and day 31) and relative differences ([day 0-day 31] x 100/day 0) were also evaluated. 
Results were considered significant if the p value was inferior to 0.05. The statistical analysis was 
done using the software SAS version 9.4.*** 
 
Results 
Description of the study population 
Fifteen patients, 8 (53.3%) women and 7 (46.7%) men, with a median age of 51.2 years (IQR:   39.7-
58.0 years) were included. They were recruited in the three participating centers (10 at CHC, 3 at CHU 
and 2 at CHR). The characteristics of the patients are described in Table 1. Two patients were lost to 
follow-up and could not be assessed for efficacy. Those were considered as non-responders and their 
data at baseline were used for response assessment. 
Impact on the number of smooth or liquid stools between day 0 and day 31 
The mean number of smooth or liquid stools significantly decreased between day 0 and day 31 (6.45 ± 
1.22 vs 3.84 ± 2.19; p< 0.0001). More specifically, the median (IQR) of patient's mean number of liquid 
stools decreased from 6.29 (5.1-7.3) to 3.7 (1.6-6.0) (p = 0.0001) (Figure 1(a)) while the median (IQR) 
of patient's mean number of smooth stools did not change significantly (0 (0-0.6) vs 0.14 (0-0.7); p = 
0.69) (Figure 1(b)). 
We also observed a significant decrease of the median (IQR) of patient's mean number of bowel 
movements, from 6.9 (5.6-7.6) to 4.6 (2.6-6.0) (p<0.0001) between day 0 and day 31 (Figure 1(c)). 
The median (IQR) of the maximum number of bowel movements also significantly decreased, from 9 
(7-9) to 5 (4-8) (p = 0.0009) between day 0 and day 31 (Figure 1(d)). 
Safety 
Among the fifteen patients included in the study, only four (26.7%) presented an adverse event: 
abdominal pain in 1; nausea and abdominal pain in 2; nausea, abdominal pain and thoracic 
oppression in 1. None of them presented SAEs. 
Other assessments 
Ten out of the 15 patients (66.7%) responded to the treatment with a decrease of at least 25% of liquid 
or smooth stools per day, and 8/15 (53.3%) responded to the treatment with a decrease of at least 2 
liquid or smooth stools per day. 
We observed a significant decrease of the HBI between day 0 and day 31, from 9.8 + 2.6 to 5.4 + 4.4 
(p = 0.0006). At day 31, five (33.3%) patients presented an HBI <5 indicating a remission (Figure 2(a)). 
We additionally observed a significant improvement of the quality of life, evaluated by the IBDQ, 
between baseline and day 31, from 115 + 25.4 to 147 + 37.9 (p = 0.0012) (Figure 2(b)). 
There was no significant change in CRP between day 0 and day 31 (p = 0.26) (Figure 3(a)) and no 
significant change in fecal calprotectin (p = 0.19) (Figure 3(b)). 
Table 1. Characteristics of the patients (N = 15). 
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Age (years)  15  51.2 39.7-58.0 
Sex W 
M 
15 8 (53.3) 
7 (46.7) 
  
Disease duration (years)  15  14.0 5.0-29.0 
Weight (kg)  15  72.8 62.0-80.4 
Height (m)  15  1.72 1.7-1.8 
BMI (kg/m
2
)  15  24.1 20.9-28.4 
Previous intestinal resection  15 11 (73.3)   
Previous cholecystectomy  15 4 (26.7)   
Loperamide  14 5 (35.7)   
Cholestyramine  14 2 (14.3)   
Mesalazine  15 2 (13.3)   
Steroids  15 4 (26.7)   
Anti-TNF  15 8 (53.3)   
Immunosuppressive drugs  15 7 (46.7)   
CRP (mg/l) at baseline  7  3.9 0.4-6.7 
Fecal calprotectin (µg/g) at baseline  14  177 32.0-211 
HBI at baseline  11  10.0 9.0-12.0 
IBDQ at baseline  14  119 98.0-135 
Patients' seven days mean number of stools at 
baseline 
 15  6.9 5.6-7.6 
Patients' seven days mean number of liquid 
stools at baseline 
 15  6.29 5.1-7.3 
Patients' seven days mean number of smooth 
stools at baseline 
 15  0.0 0.0-0.6 
Patients' seven days maximum number of 
stools at baseline 
 15  9.0 7.0-9.0 
IQR: Interquartile Range; BMI: Body Mass Index; CRP: C-reactive protein; HBI: Harvey-Bradshaw Index; IBDQ: Inflammatory 
bowel Disease Questionnaire. 
 
Discussion 
To our knowledge, this is the first study available in the literature evaluating the efficacy and safety of 
octreotide in CD patients with refractory diarrhea. 
Diarrhea is one of the main incapacitating symptoms of CD. It is significantly correlated with an 
impaired quality of life [9,10]. It is therefore one of the major parameters included in various indexes of 
CD activity and quality of life [7,8,11-14]. 
For the assessment of the effect of new treatments in CD, the Food and Drug Administration (FDA) is 
moving from the Crohn's Disease Activity Index (CDAI) [11] to patient-reported outcomes (PROs) and 
objective measures of the disease, such as findings from endoscopy [15,16]. PROs are direct 
responses from patients about how they feel or function in relation to a health condition and its therapy 
without interpretation by the physicians [17]. PROs can evaluate symptoms, signs, functional status, 
perceptions, or other aspects such as convenience and tolerability [17]. PROs will become an 
important aspect of assessing activity of inflammatory bowel diseases (IBD) [15,16]. Several disease-
specific scales have been developed to assess these PROs and are now commonly used in clinical 
trials [15]. Outcomes reported by patients in clinical trials of IBD initially focused on quality of life. 
Recently, considered factors include fatigue, depression, anxiety, and work productivity [15,18]. 





Figure 1. Evolution of the number of stools between day 0 and day 31. (a) liquid stools, (b) smooth 
stools, (c) total number of stools, (d) maximum number of stools. 
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Figure 2. Evolution of CD activity assessed by the Harvey-Bradshaw Index (HBI) (a) and of quality of 
life assessed by the IBDQ (b) between day 0 and day 31. 
 
 
Figure 3. Evolution of biological parameters (CRP measured locally (a), and fecal calprotectin 
measured centrally (b)) between day 0 and day 31. 
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The mechanisms of diarrhea in CD are complex and multifactorial. Malabsorption, osmotic 
mechanisms, secretory, and motility anomalies may be involved. Diarrhea is usually significantly 
improved by specific CD treatments (steroids, immunosuppressive drugs, and biologics). However, in 
some cases, diarrhea persists despite these treatments and becomes refractory. The mechanisms of 
this refractory diarrhea can be multiple. It can be related to an incomplete control of the intestinal 
lesions despite an optimization of CD treatment which is considered maximal. In other cases, despite 
a complete control of the intestinal lesions, a functional diarrhea may persist. In these situations, 
loperamide, antibiotics for small bowel overgrowth and cholestyramine may be useful, especially in 
patients with previous intestinal resection. However, some patients are also resistant to these 
treatments. 
Refractory diarrhea was defined in the present study by at least a mean of five smooth or liquid stools 
per day (mean of the number of stools per day over the last seven days prior to baseline) despite a 
normal CRP and an optimized specific CD treatment including immunosuppressive drugs and/or anti-
TNF. Patients were excluded of the study if they presented diarrhea due to another mechanism (small 
bowel microbial proliferation, lactose intolerance, irradiation, chemotherapy, neoplasia, or ischemia). 
In these situations of CD associated refractory diarrhea, our results suggest a potential efficacy of 
octreotide. Octreotide can improve diarrhea through different mechanisms: it can have an impact on 
the motility by prolonging the mouth-to-caecum transit time [1]; it can also have an effect on the 
gastrointestinal tract secretion [2] by increasing the intestinal absorption in the jejunum and the ileum 
and reducing the plasma VIP concentrations, the daily stool frequency and the weight of the stools. 
Through this effect on diarrhea, octreotide also improved CD activity score (HBI) and health related 
quality of life (IBDQ). 
Octreotide can also have a potential immunomodulatory effect [4] by interacting directly with its 
specific receptors that are expressed on the intestinal epithelial cells. It can down-regulate pro-
inflammatory mediators secretion by a mechanism involving the regulation of transcription. These 
findings suggest that somatostatin and its analogs may play an active role in regulating the mucosal 
inflammatory response of intestinal epithelial cells after physiological and pathological stimulations 
such as bacterial invasion. However, our results do not suggest any significant effect of this kind since 
there was no significant change in CRP and fecal calprotectin. 
The safety profile of octreotide was also favorable without any SAEs and only mild nonspecific AEs 
reported by a minority of patients. These results are similar to those published in the literature [19,20]. 
Conclusions 
In this uncontrolled open-label study, octreotide appeared safe and efficacious in patients with CD 
refractory diarrhea, in addition to specific CD treatments. It significantly improved the number of liquid 
or smooth stools, the HBI and the IBDQ. 
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